Join to view full profile
1211 Fish Hatchery RdMadison, WI 53715
Phone+1 608-252-8000
Fax+1 608-824-4949
Dr. Runaas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2014 - 2017
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2010 - 2013
University of Wisconsin School of Medicine & Public HealthClass of 2010
Certifications & Licensure
WI State Medical License 2012 - 2027
MI State Medical License 2014 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2020 Mar 01
Publications & Presentations
PubMed
- Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.Guru Subramanian Guru Murthy, Bijal Shah, Talha Badar, Jessica Leonard, Adam DuVall
Leukemia. 2026-09-14 - Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Lyndsey Runaas, Salena Fank, Katie Palen, Aniko Szabo, Lisa E Rein
Blood Advances. 2026-04-28 - 5 citationsCHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.Andrew S Artz, Brent Logan, Wael Saber, Nancy Geller, Anna Bellach
Blood Advances. 2026-03-10
Abstracts/Posters
- A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)Lyndsey Runaas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I StudyLyndsey Runaas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
What 17 Leaders Wish Medical Students Learned About Cancer CareSeptember 10th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: